Eyeing an IPO, Sutro retools its $1B I/O deal with Celgene but stays focused on BCMA
In the three years that Sutro and Celgene have been working under the umbrella of a billion-dollar deal, Sutro CEO Bill Newell expects his research …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
